0001235802-20-000006.txt : 20200207
0001235802-20-000006.hdr.sgml : 20200207
20200207164525
ACCESSION NUMBER: 0001235802-20-000006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200205
FILED AS OF DATE: 20200207
DATE AS OF CHANGE: 20200207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rizzo Matthew
CENTRAL INDEX KEY: 0001732511
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34951
FILM NUMBER: 20588063
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xtant Medical Holdings, Inc.
CENTRAL INDEX KEY: 0001453593
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 205313323
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 664 CRUISER LANE
CITY: BELGRADE
STATE: MT
ZIP: 59714
BUSINESS PHONE: 406-388-0480
MAIL ADDRESS:
STREET 1: 664 CRUISER LANE
CITY: BELGRADE
STATE: MT
ZIP: 59714
FORMER COMPANY:
FORMER CONFORMED NAME: Bacterin International Holdings, Inc.
DATE OF NAME CHANGE: 20100615
FORMER COMPANY:
FORMER CONFORMED NAME: K KITZ INC
DATE OF NAME CHANGE: 20090108
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2020-02-05
0
0001453593
Xtant Medical Holdings, Inc.
XTNT
0001732511
Rizzo Matthew
664 CRUISER LANE
BELGRADE
MT
59714
1
0
1
0
Common Stock, $0.000001 par value
2020-02-05
4
A
0
70423
0
A
91256
D
These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and will vest and become issuable with respect 35,211 shares on February 15, 2021 and with respect to 35,212 shares on February 15, 2022, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.
Includes (i) 70,423 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date; and (ii) 20,833 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.
See Exhibit 99.1
Each of ROS Acquisition, ORO II, Advisors, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.
/s/ Amy Culbert, attorney-in-fact
2020-02-07
EX-99.1
2
exhibit99-1.txt
EXHIBIT 99.1
The Reporting Person is an employee of OrbiMed Advisors
LLC (Advisors), a registered adviser under the
Investment Advisors Act of 1940, as amended. Upon
vesting of the restricted stock unit award, ownership
of the shares underlying the restricted stock unit award
will be transferred to ROS Acquisition Offshore LP
(ROS Acquisition) and OrbiMed Royalty Opportunities II, LP
(ORO II). Advisors is the investment manager of ROS
Acquisition. Advisors is also the investment manager of
Royalty Opportunities S.a.r.l., of which ROS Acquisition
is a wholly-owned subsidiary. OrbiMed ROF II LLC (ROF II)
is the sole general partner of ORO II, and Advisors is
the sole managing member of ROF II. By virtue of such
relationships, Advisors may be deemed to have voting and
investment power with respect to the securities held by ROS
Acquisition and ORO II and, as a result, may be deemed to
have beneficial ownership over such securities. Advisors
exercises its investment and voting power through a
management committee comprised of Carl L. Gordon, Sven H.
Borho, and Jonathan T. Silverstein, each of whom disclaims
beneficial ownership of the securities held by ROS
Acquisition and ORO II.